Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice.

Accurate determination of the contributions of oncogenes toward tumor progression requires their regulation. Herein, we created transgenic mice with prostate-specific expression of ligand-inducible FGFR1 or FGFR2, based on lipid-permeable dimerizing molecules, called chemical inducers of dimerization. Despite extensive homology and equivalent expression by both chimeric receptors in the ventral prostate gland, only FGFR1 triggers detectable nuclear translocation of Erk and progression to prostatic intraepithelial neoplasia (PIN). Induction of PIN grade I-II, indicated by multiple layers of atypical cells, is seen consistently by 12 weeks of chemical inducers of dimerization treatment. By 6 months, more extensive nuclear atypia, thickened "reactive" stroma, and basement membrane herniation occurs, corresponding to PIN IV. By timed removal of FGFR1 signaling, we show that induced hyperplasia is reversible until extensive intraductal vascularization occurs, but continued progression requires prolonged FGFR1 signaling. Additionally, by highlighting differences between the two receptors and creating the foundation for controlling FGFR1 signaling during prostate cancer progression, a model of early stage prostate cancer is established for developing targeted intervention directed toward the FGFR signaling axis.

[1]  B. Foster,et al.  Peptide Growth Factors and Prostate Cancer: New Models, New Opportunities , 1998, Cancer and Metastasis Reviews.

[2]  M. Ittmann,et al.  Chronic activity of ectopic type 1 fibroblast growth factor receptor tyrosine kinase in prostate epithelium results in hyperplasia accompanied by intraepithelial neoplasia , 2004, The Prostate.

[3]  Mustafa Ozen,et al.  Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation. , 2003, Cancer research.

[4]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[5]  B. Foster,et al.  Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression , 2003, The Prostate.

[6]  B. Foster,et al.  Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant negative FGFR2iiib promotes the emergence of neuroendocrine phenotype in prostate glands of transgenic mice. , 2002, Differentiation; research in biological diversity.

[7]  R. Cardiff,et al.  Fibroblast growth factor 8 isoform B overexpression in prostate epithelium: a new mouse model for prostatic intraepithelial neoplasia. , 2002, Cancer research.

[8]  Jose J. Galvez,et al.  Prostatic intraepithelial neoplasia in genetically engineered mice. , 2002, The American journal of pathology.

[9]  M. Shen,et al.  Mouse models of prostate carcinogenesis. , 2002, Trends in genetics : TIG.

[10]  S. Tsai,et al.  Ectopic expression of FGF-3 results in abnormal prostate and Wolffian duct development , 2002, Oncogene.

[11]  L. Devi,et al.  G-protein-coupled receptor dimerization: modulation of receptor function. , 2001, Pharmacology & therapeutics.

[12]  M. Kan,et al.  Growth inhibition by keratinocyte growth factor receptor of human salivary adenocarcinoma cells through induction of differentiation and apoptosis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  I. Eltoum,et al.  Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). , 2001, Cancer research.

[14]  T. Clackson,et al.  Intravenous Safety and Pharmacokinetics of a Novel Dimerizer Drug, AP1903, in Healthy Volunteers , 2001, Journal of clinical pharmacology.

[15]  P. Chaurand,et al.  A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. , 2001, Cancer research.

[16]  P. Roy-Burman,et al.  Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation , 2001, Mechanisms of Development.

[17]  R. Matusik,et al.  A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. , 2000, Endocrinology.

[18]  J. Schlessinger,et al.  Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. , 2000, Molecular cell.

[19]  D. Chopin,et al.  Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer , 1999, Oncogene.

[20]  E. Fearon,et al.  Cancer progression , 1999, Current Biology.

[21]  T. Khan,et al.  Improved artificial death switches based on caspases and FADD. , 1999, Human gene therapy.

[22]  B. Foster,et al.  The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. , 1999, Cancer research.

[23]  C. Cordon-Cardo,et al.  Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[24]  D. Spencer,et al.  Synthetic activation of caspases: artificial death switches. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  A. Matsubara,et al.  Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells. , 1997, Cancer research.

[26]  K. Peterson,et al.  A proliferation switch for genetically modified cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P. Leder,et al.  Keratinocyte growth factor induces mammary and prostatic hyperplasia and mammary adenocarcinoma in transgenic mice. , 1996, Oncogene.

[28]  J. Rosen,et al.  Metastatic prostate cancer in a transgenic mouse. , 1996, Cancer research.

[29]  S. Schreiber,et al.  A general strategy for producing conditional alleles of Src-like tyrosine kinases. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[30]  R. Matusik,et al.  Prostate cancer in a transgenic mouse. , 1995, Proceedings of the National Academy of Sciences of the United States of America.